Vitrolife（VITR）株式概要
Vitrolife AB（publish）は、ヨーロッパ、中東、アフリカ、アジア太平洋、アメリカ大陸で生殖補助医療製品を提供している。 詳細
VITR Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Vitrolife AB (publ) 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | SEK 91.80 |
| 52週高値 | SEK 153.50 |
| 52週安値 | SEK 84.00 |
| ベータ | 1.71 |
| 1ヶ月の変化 | 3.55% |
| 3ヶ月変化 | -14.04% |
| 1年変化 | -32.45% |
| 3年間の変化 | -37.55% |
| 5年間の変化 | -81.73% |
| IPOからの変化 | 1,192.96% |
最新ニュース
ナラティブ更新 • Aug 12
VITR: CEO Transition And Higher Margin Outlook Will Support Future Upside
Analysts have reset their price target for Vitrolife from SEK 215 to SEK 155. They adjusted assumptions around discount rates, revenue growth, profit margins and a lower future P/E multiple in their updated models.
ナラティブ更新 • Jul 28
VITR: Leadership Transition And Revised Outlook Will Shape Fairly Balanced Prospects
Analysts have reset their view on Vitrolife with a lower fair value estimate, moving from SEK 141.0 to SEK 95.0. The change reflects updated assumptions on the discount rate, revenue growth, profit margin and future P/E expectations. What’s in the News for Vitrolife Vitrolife announced that CEO Bronwyn Brophy O'Connor has decided to leave the company to take a CEO role in a different area of the medtech industry.
ナラティブ更新 • Jul 14
VITR: Leadership Transition And Bearish Research Will Set Up Future Re-Rating Potential
Analysts have trimmed their fair value estimate for Vitrolife from SEK162.75 to SEK130.20, citing a slightly higher discount rate, modest adjustments to revenue growth and profit margin assumptions, and more conservative future P/E expectations following recent bearish research and a downgrade. What’s in the News for Vitrolife Vitrolife announced that CEO Bronwyn Brophy O'Connor has resigned to take a CEO role in another part of the medtech industry.ナラティブ更新 • Jun 30
VITR: Higher Discount Rate Reset Will Likely Unlock Future Upside
The Vitrolife analyst price target has been trimmed from SEK 230 to SEK 215, as analysts cite a higher required discount rate and a lower assumed future P/E multiple following more cautious research, including a downgrade from Pareto. What’s in the News for Vitrolife Vitrolife AB (publ) announced that CEO Bronwyn Brophy O'Connor has decided to leave the company to take a CEO role elsewhere in the medtech industry.Recent updates
ナラティブ更新 • Aug 12
VITR: CEO Transition And Higher Margin Outlook Will Support Future Upside
Analysts have reset their price target for Vitrolife from SEK 215 to SEK 155. They adjusted assumptions around discount rates, revenue growth, profit margins and a lower future P/E multiple in their updated models.ナラティブ更新 • Jul 28
VITR: Leadership Transition And Revised Outlook Will Shape Fairly Balanced Prospects
Analysts have reset their view on Vitrolife with a lower fair value estimate, moving from SEK 141.0 to SEK 95.0. The change reflects updated assumptions on the discount rate, revenue growth, profit margin and future P/E expectations. What’s in the News for Vitrolife Vitrolife announced that CEO Bronwyn Brophy O'Connor has decided to leave the company to take a CEO role in a different area of the medtech industry.ナラティブ更新 • Jul 14
VITR: Leadership Transition And Bearish Research Will Set Up Future Re-Rating Potential
Analysts have trimmed their fair value estimate for Vitrolife from SEK162.75 to SEK130.20, citing a slightly higher discount rate, modest adjustments to revenue growth and profit margin assumptions, and more conservative future P/E expectations following recent bearish research and a downgrade. What’s in the News for Vitrolife Vitrolife announced that CEO Bronwyn Brophy O'Connor has resigned to take a CEO role in another part of the medtech industry.ナラティブ更新 • Jun 30
VITR: Higher Discount Rate Reset Will Likely Unlock Future Upside
The Vitrolife analyst price target has been trimmed from SEK 230 to SEK 215, as analysts cite a higher required discount rate and a lower assumed future P/E multiple following more cautious research, including a downgrade from Pareto. What’s in the News for Vitrolife Vitrolife AB (publ) announced that CEO Bronwyn Brophy O'Connor has decided to leave the company to take a CEO role elsewhere in the medtech industry.ナラティブ更新 • Jun 16
VITR: Governance Reforms And Softer Street Sentiment Will Support Future Upside Potential
Analysts have trimmed their price expectations for Vitrolife, with the consensus target moving slightly lower to SEK 162.75 as some now see a more cautious outlook following recent downgrades. Key valuation inputs such as the discount rate and assumed future P/E have been adjusted only marginally.ナラティブ更新 • Jun 01
VITR: Governance Reforms And Softer Street Sentiment Will Support Future Upside Potential
Analysts have trimmed their price target on Vitrolife to SEK162.75 from SEK172.20, citing slightly higher discount rate assumptions, more cautious revenue growth expectations, softer profit margin estimates, and a modestly lower future P/E multiple following recent bearish Street research, including a downgrade from Pareto. What's in the News CEO Bronwyn Brophy O'Connor has resigned to take a CEO role elsewhere in the medtech industry, and the Board has started a recruitment process for a new CEO.ナラティブ更新 • May 12
VITR: Governance Reforms And Higher P/E Expectations Will Support Future Upside Potential
Vitrolife's analyst price target has been adjusted from SEK 162.67 to SEK 172.20. Analysts point to modest tweaks in fair value assumptions, discount rate, revenue growth, profit margin and future P/E forecasts, even as some research houses, such as Pareto, have turned more cautious on the stock.ナラティブ更新 • Apr 27
VITR: Governance Reforms And Reset Expectations Will Support Future Upside Potential
Vitrolife’s analyst price target has been trimmed slightly from SEK 163.40 to about SEK 162.70, as analysts factor in updated assumptions on growth, margins and future P/E, and reflect the more cautious tone seen in recent research such as Pareto’s downgrade. Analyst Commentary Bullish Takeaways Bullish analysts see the revised target near SEK 162.70 as still implying upside relative to where caution has already been factored into growth, margin and P/E assumptions.ナラティブ更新 • Apr 12
VITR: Governance Amendments And Steady Assumptions Will Support Future Upside
Analysts have reduced their price target for Vitrolife to SEK 163.40 from SEK 176.75, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News Vitrolife AB (publ) has proposed amendments to its Articles of Association to be decided at the Annual General Meeting scheduled for May 5, 2026.ナラティブ更新 • Mar 29
VITR: Stable Fair Value And Tweaked Assumptions Will Support Future Upside
Analysts have kept Vitrolife's fair value estimate broadly unchanged at SEK 176.75, with only minor tweaks to inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions, which has driven a very small adjustment to their price target framework. Valuation Changes Fair Value Estimate was kept stable at SEK 176.75, indicating no change in the central valuation outcome.ナラティブ更新 • Mar 13
VITR: Genetic Services Restructuring And Impairment Will Underpin Future Upside Potential
Analysts have kept their SEK 176.75 price target for Vitrolife broadly unchanged, making only very small adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions to reflect fine tuning in their models rather than a shift in their overall view. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, tied to the Igenomix acquisition (company announcement).ナラティブ更新 • Feb 26
VITR: Genetic Services Restructuring And Impairment Will Support Future Upside Potential
Analysts have left their SEK 176.75 price target for Vitrolife unchanged, with only minimal tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, linked to the Igenomix acquisition (company announcement).ナラティブ更新 • Feb 11
VITR: Restructuring Of Genetic Services Will Drive Future Upside Potential
Analysts have trimmed their price target on Vitrolife to €176.75 from €187, reflecting updated assumptions that include a higher discount rate, a higher future P/E multiple, and revised expectations for revenue growth and profit margins. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, linked to the Igenomix acquisition (Key Developments).ナラティブ更新 • Jan 27
VITR: Restructuring And Goodwill Impairment Will Drive Future Upside Potential
Analysts have trimmed their price target on Vitrolife from SEK188.75 to SEK187.00, reflecting adjustments to revenue growth and discount rate assumptions, along with updated views on profit margin and future P/E levels. What's in the News Vitrolife plans a restructuring program for its genetic services business, targeting annualised savings of SEK 65 million.ナラティブ更新 • Jan 10
VITR: Restructuring And Goodwill Impairment Will Support Future Upside Potential
Analysts have maintained their fair value estimate for Vitrolife at SEK 188.75, with only minor technical adjustments to the discount rate and future P/E assumptions shaping the updated price target narrative. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, related to the Igenomix acquisition (company announcement).ナラティブ更新 • Dec 25
VITR: Restructuring And Goodwill Impairment Will Support Future Upside Potential
Analysts have slightly reduced their price target on Vitrolife, trimming fair value by SEK 4.75 to SEK 188.75, as modestly higher long term growth assumptions are offset by a small downgrade to profitability and a lower expected valuation multiple. What's in the News Vitrolife plans to record a SEK 5.4 billion goodwill impairment in the fourth quarter of 2025 related to the Igenomix acquisition (company announcement).分析記事 • Dec 18
There's No Escaping Vitrolife AB (publ)'s (STO:VITR) Muted Revenues
Vitrolife AB (publ)'s ( STO:VITR ) price-to-sales (or "P/S") ratio of 5.2x might make it look like a buy right now...ナラティブ更新 • Dec 11
VITR: Higher Long Term Revenue Outlook Will Support Further Upside
Analysts have nudged their price target on Vitrolife slightly higher to SEK 193.50 from SEK 193.00, citing marginally stronger long term revenue growth expectations that more than offset a modest uptick in the assumed discount rate and a slightly lower forecast profit margin. Valuation Changes Fair Value Estimate: unchanged at SEK 193.5 per share, indicating no revision to the intrinsic value despite minor model adjustments.ナラティブ更新 • Nov 27
VITR: Current Metrics And Stable Margins Will Support Further Upside
Analysts have maintained their fair value price target for Vitrolife at SEK 193.50, citing steady expectations for the company's growth, profitability, and valuation metrics. Valuation Changes Consensus Analyst Price Target: Unchanged at SEK 193.50.分析記事 • Nov 26
Vitrolife (STO:VITR) Seems To Use Debt Quite Sensibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...ナラティブ更新 • Nov 11
VITR: Stable Profitability And Marginal Rate Shift Will Drive Future Upside
Narrative Update on Vitrolife Analyst Price Target Vitrolife's analyst price target remains unchanged at SEK 193.50. Analysts cite only minor adjustments in growth and profitability forecasts, affirming their previous valuation stance.ナラティブ更新 • Oct 28
Profit Margins And Revenue Outlook Will Support Recovery Trends Ahead
Narrative Update on Vitrolife Analyst Price Target Analysts have raised Vitrolife’s fair value estimate from SEK191.75 to SEK193.50. They highlight the company's improved profit margin outlook and stronger projected revenue growth as key drivers behind the revised target.分析記事 • Oct 28
Vitrolife AB (publ) (STO:VITR) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Investors in Vitrolife AB (publ) ( STO:VITR ) had a good week, as its shares rose 6.6% to close at kr151 following the...ナラティブ更新 • Oct 14
US IVF Treatment Rebound And APAC Reimbursements Will Drive Recovery
Analysts have lowered their price target for Vitrolife from SEK 202.50 to SEK 191.75. This reflects updated expectations for slower revenue growth and profit margins, as well as a slightly higher discount rate.分析記事 • Aug 25
Vitrolife AB (publ)'s (STO:VITR) Shares Lagging The Industry But So Is The Business
Vitrolife AB (publ)'s ( STO:VITR ) price-to-sales (or "P/S") ratio of 5.3x might make it look like a strong buy right...新しいナラティブ • Jul 28
US IVF Treatment Rebound And APAC Reimbursements Will Drive Recovery
Recovery in IVF procedure volume and expansion in key regions will drive organic revenue growth and margin improvement as market conditions stabilize.分析記事 • Jul 08
Vitrolife AB (publ)'s (STO:VITR) Intrinsic Value Is Potentially 68% Above Its Share Price
Key Insights Vitrolife's estimated fair value is kr242 based on 2 Stage Free Cash Flow to Equity Current share price of...分析記事 • Jun 20
Here's Why Vitrolife (STO:VITR) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Apr 25
Vitrolife AB (publ)'s (STO:VITR) Price Is Right But Growth Is Lacking
Vitrolife AB (publ)'s ( STO:VITR ) price-to-sales (or "P/S") ratio of 5.4x might make it look like a buy right now...分析記事 • Mar 13
Here's Why Vitrolife (STO:VITR) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Feb 20
Estimating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)
Key Insights Vitrolife's estimated fair value is kr216 based on 2 Stage Free Cash Flow to Equity Vitrolife's kr213...分析記事 • Nov 27
Is Vitrolife (STO:VITR) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Aug 21
Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vitrolife fair value estimate is kr204 Current share price of...分析記事 • Jul 20
Vitrolife AB (publ) Just Beat EPS By 16%: Here's What Analysts Think Will Happen Next
Vitrolife AB (publ) ( STO:VITR ) just released its quarterly report and things are looking bullish. Vitrolife beat...分析記事 • Jul 18
Vitrolife AB (publ) (STO:VITR) Shares Fly 32% But Investors Aren't Buying For Growth
The Vitrolife AB (publ) ( STO:VITR ) share price has done very well over the last month, posting an excellent gain of...分析記事 • Apr 03
Vitrolife (STO:VITR) Is Carrying A Fair Bit Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Mar 07
A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vitrolife fair value estimate is kr215 With kr186 share price...分析記事 • Feb 05
Vitrolife AB (publ) Just Missed Earnings; Here's What Analysts Are Forecasting Now
The yearly results for Vitrolife AB (publ) ( STO:VITR ) were released last week, making it a good time to revisit its...分析記事 • Jan 05
Vitrolife AB (publ)'s (STO:VITR) Share Price Matching Investor Opinion
With a price-to-earnings (or "P/E") ratio of 62.5x Vitrolife AB (publ) ( STO:VITR ) may be sending very bearish signals...分析記事 • Dec 15
Here's Why We Think Vitrolife (STO:VITR) Is Well Worth Watching
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...分析記事 • Nov 27
Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)
Key Insights Vitrolife's estimated fair value is kr193 based on 2 Stage Free Cash Flow to Equity With kr173 share...分析記事 • Nov 06
Is Vitrolife (STO:VITR) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...株主還元
| VITR | SE Biotechs | SE 市場 | |
|---|---|---|---|
| 7D | -0.05% | 2.0% | -0.7% |
| 1Y | -32.5% | 25.3% | 11.2% |
業界別リターン: VITR過去 1 年間で25.3 % の収益を上げたSwedish Biotechs業界を下回りました。
リターン対市場: VITRは、過去 1 年間で11.2 % のリターンを上げたSwedish市場を下回りました。
価格変動
| VITR volatility | |
|---|---|
| VITR Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.1% |
| 10% least volatile stocks in SE Market | 3.1% |
安定した株価: VITR 、 Swedish市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: VITRの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1989 | 1,103 | Bronwyn Brophy O´Connor | www.vitrolife.com |
Vitrolife AB (publish)はヨーロッパ、中東、アフリカ、アジア太平洋、アメリカ大陸で生殖補助医療製品を提供している。精子処理、卵子回収針、マイクロマニピュレーションピペット、タイムラプスシステム、評価ツール、レーザーとイメージングシステム、IVF培地とオイル、胚移植、凍結保存、ゲノミクスキットを提供。また、eWitnessや、ディッシュ、ピペット、チューブ、VitroTempなどのラボウェア製品も提供している。ビトロライフAB（publ）は1989年に設立され、スウェーデンのヨーテボリを拠点としている。
Vitrolife AB (publ) 基礎のまとめ
| VITR 基礎統計学 | |
|---|---|
| 時価総額 | SEK 12.43b |
| 収益（TTM） | -SEK 4.98b |
| 売上高(TTM) | SEK 3.39b |
3.7x
P/Sレシオ-2.5x
PER（株価収益率VITR は割高か？
公正価値と評価分析を参照収益と収入
| VITR 損益計算書（TTM） | |
|---|---|
| 収益 | SEK 3.39b |
| 売上原価 | SEK 1.38b |
| 売上総利益 | SEK 2.01b |
| その他の費用 | SEK 6.99b |
| 収益 | -SEK 4.98b |
直近の収益報告
Jun 30, 2026
次回決算日
Oct 22, 2026
| 一株当たり利益（EPS） | -36.80 |
| グロス・マージン | 59.23% |
| 純利益率 | -146.99% |
| 有利子負債／自己資本比率 | 18.1% |
VITR の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
1.2%
現在の配当利回り-3%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/20 13:02 |
| 終値 | 2026/08/20 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Vitrolife AB (publ) 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11
| アナリスト | 機関 |
|---|---|
| null null | ABG Sundal Collier |
| Kallum Titchmarsh | BofA Global Research |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |